Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Te-Wu Chou"'
Autor:
Shih-Jie Jhuo, I-Hsin Liu, Wei-Chung Tsai, Te-Wu Chou, Yi-Hsiung Lin, Bin-Nan Wu, Kun-Tai Lee, Wen-Ter Lai
Publikováno v:
Molecules, Vol 25, Iss 16, p 3606 (2020)
Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mic
Externí odkaz:
https://doaj.org/article/e4c575f07bf547678224fe5f3aca8afa
Autor:
Te-Wu Chou, 周德武
101
Hepatoma-derived growth factor (HDGF) is a nuclear growth factor that is involved in the development of liver fibrosis. HDGF regulated the TGF-β expression while hepatocyte exposed to collagen matrix in vitro. Besides, HDGF gene delivery in
Hepatoma-derived growth factor (HDGF) is a nuclear growth factor that is involved in the development of liver fibrosis. HDGF regulated the TGF-β expression while hepatocyte exposed to collagen matrix in vitro. Besides, HDGF gene delivery in
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/15550000213823018718
Autor:
Shih-Jie Jhuo, Yi-Hsiung Lin, I-Hsin Liu, Bin-Nan Wu, Te-Wu Chou, Kun-Tai Lee, Wen-Ter Lai, Wei-Chung Tasi
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 22; Issue 11; Pages: 6105
International Journal of Molecular Sciences, Vol 22, Iss 6105, p 6105 (2021)
International Journal of Molecular Sciences; Volume 22; Issue 11; Pages: 6105
International Journal of Molecular Sciences, Vol 22, Iss 6105, p 6105 (2021)
Empagliflozin (EMPA) is a sodium–glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. However, the possible benefits and me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff6dd829a6498ef849b41963335231c
http://europepmc.org/articles/PMC8200966
http://europepmc.org/articles/PMC8200966
Autor:
Wen-Ter Lai, Te-Wu Chou, Yi-Hsiung Lin, Wei-Chung Tsai, Shih-Jie Jhuo, Kun-Tai Lee, Bin-Nan Wu, I-Hsin Liu
Publikováno v:
Molecules
Molecules, Vol 25, Iss 3606, p 3606 (2020)
Volume 25
Issue 16
Molecules, Vol 25, Iss 3606, p 3606 (2020)
Volume 25
Issue 16
Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d029d0e2ac5ea390b07126a8e2c1d97
https://pubmed.ncbi.nlm.nih.gov/32784369
https://pubmed.ncbi.nlm.nih.gov/32784369